Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine are told the same thing. Your TSH is normal, so your thyroid is fine. And for a lot of people, that is where the conversation ends, even when they still feel exhausted, cold, foggy, and slow.

To understand why that can happen, you need to understand the full chain first, because the problem is not usually the medication itself.

Your thyroid produces two hormones. One is called T3, which is the biologically active form that enters your cells and drives your metabolism, your energy production, your body temperature, your mood, and dozens of other downstream functions. The other is called T4, which is essentially a storage form, a precursor molecule that your body has to convert before it can actually use it.

Here is where the math matters. Your thyroid directly produces only about 20% of the T3 circulating in your bloodstream. The other 80% does not come from your thyroid at all. It comes from your liver, your kidneys, and your gut, where enzymes strip one iodine atom off the T4 molecule and convert it into active T3. Those enzymes are called deiodinases, and they are the machinery that makes the whole system run.

So when your doctor prescribes levothyroxine, which is synthetic T4, the underlying assumption is that your body will handle that 80% conversion on its own. You take the precursor in pill form, your tissues convert it, and you end up with enough active T3 to feel normal. For a large number of people, that assumption holds. But for a meaningful portion of patients, it does not.

The most common way this gets missed is through the test being used. TSH, or thyroid stimulating hormone, is a signal your pituitary gland sends to your thyroid telling it to produce more or less hormone. When levothyroxine raises your T4 levels, your pituitary sees that, reads it as sufficient, and pulls back on TSH. So TSH normalizes. But TSH is measuring what one gland at the base of your brain is seeing. It is not measuring what is happening in the rest of your body, and it tells you nothing directly about whether that T4 is getting converted into usable T3.

A study looking at levothyroxine-treated patients with normal TSH found that those patients had T3 to T4 ratios 15 to 20% lower than people who were not on thyroid medication, and up to 40% of those patients still reported significant symptoms even with labs that appeared completely normal. That gap between the lab and the experience is not a mystery once you understand the conversion step. The T4 is there. The conversion is the question.

Three things are known to impair that conversion step. The first is selenium. Deiodinase enzymes are what biochemists call selenoproteins, meaning they require selenium as a structural component to function properly. Without adequate selenium, the enzymes that convert T4 into T3 run at reduced capacity. Studies in selenium-deficient patients show elevated free T4 alongside low T3, which is the biochemical fingerprint of a conversion bottleneck. The second factor is inflammation. Chronic systemic inflammation, the kind that comes with autoimmune conditions, metabolic dysfunction, or persistent gut issues, is known to downregulate deiodinase activity. The third is liver and gut health directly, since those are the primary conversion sites.

This is especially relevant for people with Hashimoto's thyroiditis, which is the autoimmune condition that is the most common cause of hypothyroidism in the developed world. The ongoing autoimmune activity in Hashimoto's does two things simultaneously. It destroys thyroid tissue, which reduces the 20% your thyroid makes directly. And it drives chronic inflammation that impairs the deiodinase enzymes responsible for the other 80%. You are losing output from both ends of the same pipeline, and TSH alone will not capture that.

There is also a genetic layer to this. Between 12 and 36% of people carry a variant in a gene called DIO2, which codes for one of the primary deiodinase enzymes. People with this variant have structurally reduced conversion capacity that cannot be fixed by optimizing selenium or reducing inflammation. It is a hardware limitation, not a lifestyle one. A study in the Journal of Clinical Endocrinology and Metabolism found that patients with this DIO2 variant reported lower psychological wellbeing on T4-only therapy and showed measurable improvement when T3 was added to their regimen. This is one reason why some patients do not respond to levothyroxine regardless of dose.

The practical entry point here is asking for free T3 to be tested alongside TSH. Free T3 is the fraction of T3 that is unbound and biologically available to your cells, and it is the most direct measure of whether conversion is actually happening. If free T3 is low while TSH is normal, that is the conversion gap showing up in the numbers.

If conversion is the confirmed issue, 200 micrograms of selenium per day is the most studied nutritional support for deiodinase function, and this is the kind of thing worth discussing with your provider rather than starting independently, since selenium has a relatively narrow range between adequate and excessive intake.

For people who carry the DIO2 variant or who continue to have symptoms despite optimized T4 levels and adequate selenium, some clinicians will consider combination therapy using both T4 and a small amount of T3, either as synthetic liothyronine or as desiccated thyroid extract. This approach remains a subject of debate in endocrinology, but the mechanism justifying it is not controversial. If conversion is impaired at the enzymatic level, adding the converted product directly bypasses the broken step.

The framing most people are given is that levothyroxine either works or it does not, and if TSH is normal, it worked. But the hormone your body runs on is T3, not T4, and the conversion between them is a biological process that depends on specific enzymes, specific nutrients, and a physiological environment that can be disrupted in multiple ways.

You can be perfectly medicated for your pituitary and still be running short on the one hormone that actually does the work.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness